To Assess the Efficacy and Safety of HD-6277 in Adult Patients With Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise

Launched by HYUNDAI PHARM · Oct 16, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a new treatment called HD-6277 for adults who have Type 2 Diabetes Mellitus (T2DM) and are not achieving good blood sugar control through diet and exercise alone. The study aims to find out if HD-6277 is safe and effective for people whose blood sugar levels, measured by a test called HbA1c, are between 7.0% and 10.0%. To participate, individuals must have been following a diet and exercise program for at least 8 weeks and meet certain other health criteria.

Participants in this trial can expect to be randomly assigned to receive either the study drug HD-6277 or a placebo (a substance with no active medication) for comparison. The study is being conducted at multiple locations and is currently recruiting patients. It's important to know that this trial is only for adults who do not have Type 1 diabetes or certain other health conditions, and those with a body mass index (BMI) over 40 will not be eligible. This research is crucial for finding new ways to help people manage their diabetes better.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of T2DM with HbA1c between 7.0% and 10.0% (inclusive) while on diet and exercise alone for at least 8 weeks prior to screening.
• Exclusion Criteria:
• • Type 1 diabetes or another immune-mediated diabetes syndrome
• • BMI: \> 40 kg/m2
• • C-peptide: \< 0.5ng/mL